Document:

<PAGE>
                                                                   Exhibit 10.18

[MEMORY PHARMACEUTICALS CORP. LETTERHEAD]

March 4,2002

Tony Scullion
5420 N. Ocean Drive
Apt. 2102
Singer Island, FL 33404-2543

Dear Tony:

      We are writing to you in connection with the proposed sale of Series D
Preferred Stock (the "Series D Stock") of Memory Pharmaceuticals Corp. (the
"Company") pursuant to a Preferred Stock Purchase Agreement, dated March 4,2002
(the "Purchase Agreement"), and the letter agreement of employment, dated July
2, 2001, as amended by that certain amendment dated August 6, 2001 (the
"Employment Agreement"), between the Company and you. In connection with the
Proposed Sale, we wish to clarify the following items.

      First, the sale by the Company of any shares of Series D Stock in excess
of an aggregate of $40 million of gross proceeds shall not be included in the
Company's fully diluted shares of common stock ("Common Stock") for purposes of
applying the provisions of the second sentence of Section 3(c) of the Employment
Agreement, which provisions provide for an increase in the number of shares of
Common Stock subject to the incentive stock option referred to in the first
sentence of said Section 3(c).

      Second, the provisions of said second sentence of said Section 3(c) will
cease to have effect for any sale by the Company of Common Stock or securities
convertible or exchangeable into Common Stock subsequent to the sale by the
Company of the Series D Stock pursuant to the Purchase Agreement.

      Third, any increase in the Company's fully diluted shares of Common Stock
caused by an increase, if any, in the number of shares of Series D Stock
pursuant to Section 1.4 of the Purchase Agreement shall not be included in the
Company's fully diluted shares of Common Stock for purposes of applying the
provisions of said second sentence of said Section 3(c). Section 1.4 of the
Purchase Agreement reads as follows: "If a Clinical Trial Event (defined below)
has not occurred by 5:00 P.M. (New York time) on March 4, 2003, then the
purchase price for the Series D Shares set forth in Section 1.2 of this
Agreement shall be adjusted to One Dollar Seventy-five Cents ($1.75) through the
immediate issuance to each holder of Series D Shares of additional Series D
Shares equal to the product of (i) the number of Series D Shares then held by
such holder by (ii) 0.228571 (the quotient of $.40 divided by $1.75), provided
that no fractional shares of Series D Shares shall be issued upon conversion of
any shares of Preferred Stock and in lieu of any fractional shares of Series D
Shares to which such holder would otherwise be entitled, the Company shall pay
cash equal to such fractional shares multiplied by

<PAGE>

Anthony Scullion
March 4,2002
Page 2

One Dollar Seventy-five Cents $1.75." Section 6.1 of the Purchase Agreement
reads as follows in relevant part: "'Clinical Trial Event' shall mean the
commencement of a Phase I clinical trial of a product candidate to which the
Company owns or otherwise has been licensed commercialization rights and which
Phase I clinical trial has been designed in such a way and is occurring in such
venue to allow, if such Phase I clinical trial is successful, for submission of
the results of such Phase I clinical trial to the United States Food and Drug
Administration for the purpose of commencing a Phase IIa clinical trial of such
product candidate."

      Except for the items expressly stated in this letter agreement, this
letter agreement does not amend any other terms or conditions in the Employment
Agreement.

      Please indicate your agreement with the above items by executing a
counterpart of this letter agreement in the location provided below for your
signature and returning it to the Company. We appreciate your assistance.

                                     Very truly yours,

                                     THE BOARD OF DIRECTORS OF
                                     MEMORY PHARMACEUTICALS CORP.

                                     By:    /s/  Joanne Leonard
                                            ------------------------------------
                                     Name:  Joanne Leonard
                                     Title: Secretary to the Board of Directors

ACCEPTED AND AGREED, as of the
date first above written:

/s/  Tony Scullion
-------------------------------
Tony Scullion<PAGE>
                                                                   EXHIBIT 10.19

[MEMORY COMPANY LOGO]

MEMORY PHARMACEUTICALS CORP.                             JOANNE LEONARD
100 PHILIPS PARKWAY                                      SENIOR VICE PRESIDENT
MONTVALE, NEW JERSEY 07645                               CHIEF FINANCIAL OFFICER
PHONE: (201) 802-7102
FAX: (201)  802-7190
www.memorypharma.com

February 18, 2002

James E. Barrett, Ph.D.
1231 River Road
Washington Crossing, PA 18977

Dear Jim:

      We are pleased to extend an offer to you to join our Company as Senior
Vice President of Research and Development. We look forward to you joining our
team, and are confident that you will contribute significantly to the value of
our organization. The terms of your anticipated employment by the Company are as
follows.

      1. Position. Your position will be Senior Vice President of Research and
Development, based out of the Company's offices currently located in Montvale,
New Jersey, and will report directly to the Company's President and Chief
Scientific Officer. As Senior Vice President of Research and Development, you
will be part of the Company's senior management team, and will work closely with
this team to establish strategic, value-building relationships with
pharmaceutical companies and contract research organizations. Your
responsibilities shall include, but not be limited to, managing all research and
development activities up to clinical Phase IIa studies and managing post
collaboration interface on pivotal clinical trials. In addition to performing
duties and responsibilities associated with the position of Senior Vice
President of Research and Development, from time to time the Company may assign
you other duties and responsibilities and/or may assign you to a different
location.

      As a full-time employee of the Company, you will be expected to devote
your full business time and energies to the business and affairs of the Company.
Your performance will be reviewed formally after six months of employment and
annually thereafter at the end of each calendar year.

      2. Starting Date/Nature of Relationship. It is expected that your
employment will start on April 16, 2002 (the "Start Date"). No provision of this
letter shall be construed to create an express or implied employment contract
for a specific period of time. Either you or the Company may terminate the
employment relationship at any time and for any reason, by giving at least
thirty (30) days' prior written notice to the other party.

      3. Compensation.

      (a) Your initial salary will be at the bi-weekly rate of $10,576.92
(annualized at $275,000).

      (b) You will receive incentive stock options to purchase 300,000 Shares of
Common Stock of Memory Pharmaceuticals Corp. at $0.25 per share, which will vest
in quarterly increments over a period of four (4) years as described in the
Stock Option Agreement, which you and the Company will enter into on or before
the Start Date. You will receive additional incentive stock
<PAGE>

MEMORY PHARMACEUTICALS CORP.
James E. Barrett, Ph.D.

options to purchase Shares of Common Stock of Memory Pharmaceuticals Corp.,
immediately after the closing of the Company's Series D Financing at the then
fair market value to be determined by the Company's Board of Directors (without
affecting the purchase price of the initial grant of options to acquire 300,000
shares of the Company's Common Stock), with such additional option vesting to
commence on the date of such grant in quarterly increments over a period of four
(4) years. The additional incentive stock options to purchase Shares are being
provided to allow your percentage ownership before the Series D Financing not to
be substantially diluted.

      (c) You will be eligible to receive annual bonus payments dependent on the
performance of the Company and your individual performance, subject to the
discretion of the Board of Directors. Your target bonus will be equal to
twenty-five percent (25%) of your base salary, assuming the achievement of such
Company and individual performance objectives. You will receive a one-time
annual guaranteed bonus of $25,000, payable within 30 days of your one-year
anniversary.

      (d) Upon termination for any reason, the Company will pay you within two
weeks of such termination, your current base salary earned through the
termination date, plus accrued vacation, if any, and other benefits or payments,
if any, to which you are entitled. In the event you are terminated by the
Company, without "Cause" (as hereinafter defined), then the Company will
continue to pay you your bi-weekly rate in effect at the time of termination and
provide and pay the Company's portion of your medical insurance for a period of
six (6) months. Further, for the period commencing seven months following such
termination and ending twelve months after such termination, the Company will
continue to pay you your bi-weekly rate in effect at the time of termination and
provide and pay the Company's portion of your medical insurance, except that
such severance payments made to you during this period will be reduced by all
1099 and W-2 income earned or received by you during such period, including
income earned or received from consulting services or temporary employment, and
the Company's payments for your medical insurance will terminate when you have
such coverage through any new employer before the end of the twelve month period
following your termination. The Company will reconcile such payments with you
quarterly, and any additional payments owed to you by the Company, and any
payments owed to the Company by you, will be paid respectively within two weeks
following such reconciliation period. The Company will not be obligated to
continue any such payments to you under this paragraph 3(e) in the event you
materially breach the terms under the Confidentiality Agreement (as defined
below). Notwithstanding any termination of your employment, you will continue to
be bound by the provisions of the Confidentiality Agreement.

      (e) For the purposes of this Section 3, "Cause" shall include (i) your
conviction of a felony, either in connection with the performance of your
obligations to the Company or otherwise, which adversely affects your ability to
perform such obligations or materially adversely affects the business
activities, reputation, goodwill or image of the Company, (ii) your willful
disloyalty, deliberate dishonesty, breach of fiduciary duty, (iii) your breach
of the terms of this Agreement, or your failure or refusal to carry out any
material tasks assigned to you by the Company in accordance with the terms
hereof, which breach or failure continues for a period of more than thirty (30)
days after your receipt of written notice thereof from the Company, (iv) the
commission by you of any act of fraud, embezzlement or deliberate disregard of a
significant rule or policy of the Company known to you or contained in a policy
and procedure manual provided to you which results in material loss, damage or
injury to the Company, or (v) the material breach by you of any of the
provisions of the Confidentiality Agreement substantially in the form of
Attachment A to this letter.

      4. Benefits. You will be entitled as an employee of the Company to receive
such benefits as are generally provided its employees and executives and for
which you are eligible in accordance with Company policy as in effect from time
to time. The Company retains the right to change, add or cease any particular
benefit relating to its employees and executives generally. At this time, the
Company is offering a benefit program, consisting of medical, dental, life and

                                       2
<PAGE>

MEMORY PHARMACEUTICALS CORP.
James E. Barrett, Ph.D.

short/long term disability insurance, as well as a 401(k) retirement plan and
flexible spending plan. You will be eligible for eleven paid holidays, four
floating holidays and four (4) weeks paid vacation per year. You will accrue
additional vacation days in accordance with Company policy.

      5. Relocation Expenses. The Company will pay or reimburse you for all
reasonable out-of-pocket relocation and relocation-related expenses not to
exceed $100,000, including any Tax Payment (as defined below) and any Gross-up
Payment (as defined below), which may be billed directly to the Company or paid
by you and submitted for reimbursement, including, without limitation, the
following:

      (a) costs of services of moving companies (including packing,
transportation and relocation expenses, including the transportation of
automobiles);

      (b) costs associated with your search for a new residence (including,
without limitation, the costs of airfare, automobile rental, meals and hotel
accommodations for yourself and your immediate family);

      (c) commissions payable to brokers in connection with the sale of your
current residence;

      (d) costs attendant to the sale of your current residence and the purchase
of a new residence in the Northern New Jersey area (including, without
limitation, the costs of home inspections, survey, appraisal, title insurance,
transfer fees, attorneys' fees, accountants' fees, and closing costs);

      (e) loan origination fees (points) related to the purchase of your new
residence in an amount of up to three percent (3%) of the loan amount (and the
Company will provide assistance to you relating to the selection of a mortgage
lender that will pre-qualify you for a mortgage loan to purchase your new
residence);

      (f) costs associated with commuting from your current residence to the
Company's offices (including, without limitation, the costs of airfare,
automobile rental, meals and hotel accommodations for you) for a period of up to
six months, subject to extension upon our mutual agreement;

      (g) automobile rental charges prior to establishment of a permanent
residence in Northern New Jersey;

      (h) rent and other expenses associated with temporary housing for yourself
and your immediate family for a period of up to six months (which may include up
to two months after the purchase and closing of title on your new residence),
subject to extension upon our mutual agreement; and

      (i) payment of any duplicate mortgage loan payments and house expenses to
preclude your paying for your current residence and your new residence
concurrently.

      (j) All such payments will be subject to the Company receiving reasonably
acceptable documentation evidencing the incurring of such cost, expense or fee.
In the event that it should be determined that any payment shall be due by you
for taxes of any kind or nature relating to amounts paid to you or on your
behalf by the Company in connection with your relocation as provided above
("Taxes"), the Company will deliver to you a payment equal to the amount of such
Taxes (the "Tax Payment") plus an additional payment in an amount equal to any
additional taxes payable by you applicable to your receipt of the Tax Payment
(the "Gross-Up Payment"). All such payments are fully refundable to the Company
if you leave the Company within twelve months of your Start Date.

                                       3
<PAGE>

MEMORY PHARMACEUTICALS CORP.
James E. Barrett, Ph.D.

      6. Indemnification. The Company will indemnify you in connection with any
legal proceedings related to your actions on behalf of the Company, including
after your employment with the Company.

      7. Confidentiality. The Company considers the protection of its
confidential information and proprietary materials to be very important.
Therefore, as a condition of your employment, you and the Company will become
parties to a Confidentiality and Noncompetition Agreement substantially in the
form of Attachment A to this letter (the "Confidentiality Agreement").

      8. General.

      (a) This letter, together with the Confidentiality Agreement and the Stock
Option Agreement will constitute our entire agreement as to your employment by
the Company and will supersede any prior agreements or understandings, whether
in writing or oral.

      (b) This letter shall be subject to our review of a satisfactory medical
examination.

      (c) By signing this letter, you acknowledge that you have provided to the
Company information contained in your existing personnel files, together with
supportive information, attesting to the fact that you do not have nor are aware
of any non-competition or other similar agreement with your existing or prior
employer that would restrict or prohibit your becoming employed by the Company
or providing the services for the Company contemplated by this letter.

      (d) The law of the State of New Jersey shall govern this letter.

       You may accept this offer of employment and the terms thereof by signing
the enclosed additional copy of this letter and the Confidentiality Agreement
and the Stock Option Agreement, which execution will evidence your agreement
with the terms set forth herein and therein, and returning them to the Company.

      This offer of employment will expire on February 28, 2002, unless accepted
by you prior to such date. We look forward to you joining our team, and we
believe that your skills will compliment those of our existing management team,
and that you will make a significant contribution to Memory's growth. We look
forward to your prompt response to this offer letter.

Sincerely,

/s/ Joanne Leonard
------------------
Joanne Leonard
Senior Vice President
Chief Financial Officer
Memory Pharmaceuticals Corp.

ACCEPTED AND AGREED:

/s/ James Barrett
------------------
Date: 2/22/02

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]